What Aliada Therapeutics does

Aliada Therapeutics was a Boston-based, privately-held biotechnology company founded in 2021 that focused on developing therapeutics for central nervous system (CNS) disorders, with a primary emphasis on Alzheimer's disease. The company's core scientific asset was a proprietary blood-brain barrier (BBB) crossing drug delivery platform—a technically novel method architecture intended to enable therapeutic molecules to reach the brain, where most candidate CNS drugs historically fail due to the BBB's restrictive permeability. The platform underpinned the company's pipeline, the most advanced asset of which was ALIA-1758, an investigational Alzheimer's disease drug.

Operationally, Aliada was an early-stage, pre-commercial R&D biotech with a headcount of 11-50 employees and limited disclosed capital activity: a single SEC-registered exempt offering of approximately $32 million was filed on December 30, 2022. The company had no commercial revenue, no disclosed pricing model, and no recurring customer base; its primary customer segment was pharmaceutical and biotech acquirers interested in neuroscience and Alzheimer's pipelines. Its business model was effectively a single-exit acquisition pathway, with the lead asset and platform oriented toward out-licensing or trade sale to a larger neuroscience franchise.

That pathway was realized on December 11, 2024, when AbbVie completed the acquisition of Aliada Therapeutics for $1.4 billion, integrating ALIA-1758 and the BBB-crossing platform into AbbVie's neuroscience portfolio. Post-acquisition, Aliada ceased to operate as an independent entity and became a wholly-owned subsidiary of AbbVie. The acquisition occurred against a backdrop of sharply rising industry M&A activity in Alzheimer's disease, with disclosed deal value in the indication rising 780% from $2 billion in 2022 to $18 billion in 2024.

Name

Aliada Therapeutics

Legal name

Aliada Therapeutics, Inc.

Website

https://aliadatx.com

Company type

Private

Founded year

2021

Operating status

Acquired

Headcount range

11–50 employees

Short description

Aliada Therapeutics was a Boston-based biotech developing proprietary blood-brain barrier crossing drug delivery technology for CNS disorders, with ALIA-1758 as its lead Alzheimer's candidate before AbbVie's $1.4 billion acquisition in December 2024.

Ownership category

akta.pro rank

Product category

Neuroscience Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Central nervous system therapies
• Blood-brain barrier delivery
• Alzheimer's disease treatment
• Neuroscience drug development
• Biopharmaceutical research

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Acquisition/Exit: Aliada Therapeutics was acquired by AbbVie for $1.4 billion, representing the primary monetization pathway for investors and stakeholders.

Core offering

Aliada Therapeutics developed a proprietary blood-brain barrier (BBB)-crossing drug delivery technology platform designed to enable therapeutics to reach the central nervous system, and advanced ALIA-1758, an investigational drug for Alzheimer's disease. The company was a pre-commercial R&D-stage biotech whose pipeline assets were integrated into AbbVie following the $1.4 billion acquisition in December 2024.

Product overview

Aliada Therapeutics was a biotechnology company focused on neuroscience drug development, specifically targeting Alzheimer's disease and other neurological disorders. The company's core assets included ALIA-1758, an Alzheimer's investigational drug, and a proprietary BBB-crossing drug delivery technology platform. Aliada Therapeutics was acquired by AbbVie in December 2024 for approximately $1.4 billion, integrating its neuroscience pipeline into AbbVie's research operations.

Differentiator

Problem solved

Functional benefit

Products and services

• ALIA-1758
• BBB-Crossing Drug Delivery Technology Proprietary drug delivery technology platform engineered to enable therapeutics to traverse the blood-brain barrier and reach the central nervous system. Designed to support the development of treatments for neurological disorders including Alzheimer's disease. Acquired by AbbVie in December 2024.

Quantifiable outcome

• 780% increase in Alzheimer's M&A deal value from $2B (2022) to $18B (2024)

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators3 records

Recent moves4 records

Expansion highlights3 records

Direct peers

• Denali Therapeutics: Denali Therapeutics is a direct peer: a CNS-focused biotech developing therapeutics for neurodegenerative diseases with proprietary blood-brain barrier delivery technology (e.g., Enzyme Transport Vehicle platform), making it the closest comparable on both therapeutic focus and delivery modality.
• Voyager Therapeutics: Voyager Therapeutics develops gene therapies and RNA-targeted approaches for CNS disorders, with BBB-penetrating delivery as a core engineering focus. Highly comparable on the CNS drug delivery axis though differentiated by its gene therapy modality.
• Sage Therapeutics: Sage Therapeutics is a CNS-focused biotechnology company developing therapies for neurological disorders (e.g., Zurzuvae for postpartum depression). Comparable as a focused CNS therapeutics developer with platform-based discovery, although its delivery modality differs from Aliada's BBB platform.
• Annexon Biosciences: Annexon is a clinical-stage biotech developing therapeutics for neuroinflammatory and neurodegenerative diseases. Directly comparable as a CNS-focused biotech with investigational assets targeting classical complement pathways in neurological indications.
• Athira Pharma: Athira Pharma is a clinical-stage biopharmaceutical company developing small molecule therapeutics for neurodegenerative diseases including Alzheimer's. Comparable on CNS therapeutic focus and stage of development, though its mechanism (HGF/MET modulation) differs from Aliada's BBB delivery approach.
• Biohaven Pharmaceuticals: Biohaven is a CNS-focused biopharmaceutical company developing therapies for neurological and neuropsychiatric diseases. Comparable as a focused CNS therapeutics developer with a pipeline of investigational assets, though broader in indication scope than Aliada.

Emerging players

• C2N Diagnostics: C2N Diagnostics develops diagnostic and therapeutic solutions for Alzheimer's and other neurodegenerative diseases. Comparable as a neuroscience-focused company active in the Alzheimer's space, though its primary products are diagnostics rather than therapeutics.

Broad incumbents

• Biogen: Biogen is a major biopharmaceutical company with a leading Alzheimer's franchise (Leqembi, co-developed with Eisai). Comparable as a broad incumbent in CNS/Alzheimer's therapeutics, but operates at much larger scale with multiple modalities rather than a focused BBB-delivery niche.
• Eli Lilly: Eli Lilly is a major pharmaceutical incumbent with a strong Alzheimer's franchise (Kisunla) and broad CNS pipeline. Comparable as a broad incumbent in CNS drug development, but operates at scale with a portfolio spanning many therapeutic areas beyond BBB delivery.
• AbbVie: AbbVie is the acquirer of Aliada Therapeutics and a major pharmaceutical incumbent with a significant neuroscience franchise (e.g., Vraylar). Comparable as a broad incumbent and strategic acquirer of CNS-focused biotech platforms, providing context for Aliada's exit valuation.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/aliada-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aliada Therapeutics